Sprint Bioscience AB (SPRINT) — Cash Flow-to-Debt Ratio
Sprint Bioscience AB (SPRINT) has a Cash Flow-to-Debt Ratio of -1.52x as of March 2026, meaning its operating cash flow of Skr-19.29 Million could theoretically repay -2% of its total liabilities (Skr12.69 Million) in one year. Check cash flow reinvestment rate of Sprint Bioscience AB to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sprint Bioscience AB Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Sprint Bioscience AB across 14 annual periods. Also explore total assets of Sprint Bioscience AB for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Sprint Bioscience AB (2012–2025)
Year-by-year debt coverage analysis for Sprint Bioscience AB. For market capitalisation and broader financial context, see Sprint Bioscience AB stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 4.78x | Skr83.53 Million | Skr17.48 Million | ▲ +770.6% |
| 2024 | -0.71x | Skr-23.36 Million | Skr32.78 Million | ▼ -207.8% |
| 2023 | 0.66x | Skr22.87 Million | Skr34.60 Million | ▲ +110.3% |
| 2022 | -6.40x | Skr-59.05 Million | Skr9.23 Million | ▼ -38.4% |
| 2021 | -4.62x | Skr-40.12 Million | Skr8.68 Million | ▼ -247.8% |
| 2020 | -1.33x | Skr-32.22 Million | Skr24.25 Million | ▲ +61.0% |
| 2019 | -3.40x | Skr-28.00 Million | Skr8.23 Million | ▼ -293.2% |
| 2018 | -0.87x | Skr-19.08 Million | Skr22.05 Million | ▲ +72.2% |
| 2017 | -3.12x | Skr-23.05 Million | Skr7.40 Million | ▼ -925.9% |
| 2016 | 0.38x | Skr7.93 Million | Skr21.03 Million | ▲ +1068.6% |
| 2015 | 0.03x | Skr833.54K | Skr25.81 Million | ▲ +101.4% |
| 2014 | -2.23x | Skr-10.76 Million | Skr4.83 Million | ▼ -156.8% |
| 2013 | -0.87x | Skr-3.57 Million | Skr4.11 Million | ▼ -21.3% |
| 2012 | -0.72x | Skr-2.29 Million | Skr3.20 Million | — |